Clinical Chemistry, Vol 37, 466-471, Copyright © 1991 by American Association for Clinical Chemistry

Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymometric assay with domain-specific monoclonal antibodies

M Katayama, F Hino, K Kamihagi, K Sekiguchi, K Titani and I Kato
Biotechnology Research Laboratories, Takara Shuzo Co., Ltd., Otsu, Shiga, Japan.

We found that urinary fibronectin (UFN) in cancer patients was almost all fragmented and consisted mainly of the cell-binding domain. We developed a two-site immunoenzymometric assay for UFN, using two monoclonal antibodies that both recognize this domain of fibronectin. The amount of UFN was expressed as arbitrary units per milligram of creatinine. Some 2% of the 623 healthy subjects had UFN above the clinical cutoff point (200 arb. units/mg creatinine), as did 14% of the 271 patients with nonmalignant diseases. In contrast, concentrations of UFN exceeded the cutoff point in 59% of the 589 patients with cancer. In 37 patients with gastrointestinal cancer tested for UFN and for one or more of three established serum tumor markers, UFN was found in 25, significantly more often than the other markers. These results indicated that UFN is a marker that may be helpful in evaluating many kinds of cancer.

The following articles in journals at HighWire Press have cited this article:

				M. Sánchez-Carbayo, M. Urrutia, J. M. G. de Buitrago, and J. A. Navajo Evaluation of Two New Urinary Tumor Markers: Bladder Tumor Fibronectin and Cytokeratin 18 for the Diagnosis of Bladder Cancer Clin. Cancer Res., September 1, 2000; 6(9): 3585 - 3594. [Abstract] [Full Text]